Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Dermatology
    • IV cetirizine better...

    IV cetirizine better than IV diphenhydramine in acute urticaria

    Written by Medha Baranwal Baranwal Published On 2018-11-18T19:30:21+05:30  |  Updated On 18 Nov 2018 7:30 PM IST
    IV cetirizine better than IV diphenhydramine in acute urticaria

    A new study finds that intravenous (IV) cetirizine is a better alternative to IV diphenhydramine for the treatment of acute urticaria.


    The study, presented at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI) in Seattle, demonstrated that the use of IV cetirizine was associated with multiple benefits, including less adverse events and less symptom recurrence.


    Diphenhydramine, a first-generation antihistamine that is short in duration and causes sedation, anticholinergic effects, and drug interactions is the only currently available H1-antihistamine injection.


    Also Read: Diet restriction leads to complete remission in Chronic Spontaneous Urticaria

    In this phase 3 multi-center, parallel-group, randomized, double-blind, active-controlled clinical trial, researchers compared diphenhydramine injection 50 mg/mL with a newly developed cetirizine 10 mg/mL injection for the treatment of the most common allergic reaction symptom: acute urticaria.


    Study participants (N=262) were randomly assigned to an IV diphenhydramine group or to an IV cetirizine group, with a primary efficacy endpoint of change from baseline in 2-hour pruritus score. Secondary endpoints were time spent in the treatment center and the need to return to the treatment center within 48 hours. Patient sedation scores were determined at 1 hour, 2 hours, and at discharge.


    Also Read: A case of Delayed pressure urticaria due to BP Cuff

    Key Findings:

    • The change from baseline in 2-hour pruritus score was shown to be statistically noninferior from IV cetirizine to IV diphenhydramine, in favor of IV cetirizine.

    • The participants treated with diphenhydramine spent an average of 2.07 hours in the treatment center compared with 1.71 hours spent by participants treated with cetirizine, and 14% of the participants treated with diphenhydramine returned to the treatment center within 48 hours compared with 5.5% of the group treated with cetirizine.

    • The cetirizine group experienced significantly less sedation at 1 hour, 2 hours, and at discharge compared with the diphenhydramine group.


    "IV cetirizine is an effective alternative to IV diphenhydramine in the treatment of acute urticaria with benefits of less sedation, less AE, earlier discharge, less symptom recurrence, and fewer return[s] to the treatment center.” concluded the authors.

    cetirizineDiphenhydraminehivesintravenousIVtreatmenturticaria
    Source : With inputs from 2018 Annual Scientific Meeting of ACAAI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok